Skip to main content
BioCentury, the Bernstein Report on BioBusiness
As published for the week of Monday, August 18, 2014


  • Cover Story: Strategy: Breathing room

    Almirall COPD assets give AZ time for respiratory pipeline to mature

    By Stephen Hansen, Associate Editor

    AstraZeneca plc's acquisition of Almirall S.A.'s respiratory assets should buy the pharma time while its respiratory pipeline matures. The deal not only gives AstraZeneca a faster route to market in the COPD combination therapy race - moving it into third place behind GlaxoSmithKline plc and Novartis AG - but also gives AZ a greater range of choices for combination therapies in two device formats in a disease space where patient preference is important.

    Inhaled therapies lead the line in AstraZeneca's respiratory franchise, but the long-term goal is to complement them with biologics for more severe disease - and AZ has one of the broadest pipelines of respiratory biologics in the industry, with two biologics in Phase III testing and a pair in Phase II.

    Full Article

Money Raised in 2014

Last week, the biotech industry raised $848 million, bringing to $36.1 billion the total raised year-to-date. In 2013, a total of $37.1 billion was raised, including $14.4 billion in debt, $10 billion in follow-ons, $2.8 billion in PIPEs and other equity, $3.9 billion in IPOs, and $5.9 billion in venture capital. Totals include overallotments and warrants, and are rounded to the nearest millions.

Subscribe Now
Free Trial